Skip to main content

FDA Approves Combo Meningitis Vaccine for Infants


June 14, 2012 — The US Food and Drug Administration (FDA) has approved a combination meningitis vaccine for infants and children aged 6 weeks through 18 months, the agency announced today.
The FDA said this is the first meningococcal vaccine that can be taken by children as young as 6 weeks of age.
The vaccine, called Menhibrix (GlaxoSmithKline Biologicals), immunizes against 2 types of bacteria: Neisseria meningitidis (serogroups C and Y) and Haemophilus influenzae type B (Hib). Each bacterium can infect the lining that surrounds the brain and spinal cord, according to the FDA.
Both meningococcal and Hib diseases can cause death or serious and permanent damage such as mental retardation and blindness. The diseases can progress rapidly, and their symptoms are hard to distinguish from those of other common childhood conditions, making them particularly dangerous for children younger than 2 years of age.
The FDA determined that Menhibrix is effective based on tests conducted with several hundred US infants and toddlers who received the vaccine. Their immune responses to the Hib component resembled those of infants and toddlers who received a vaccine against invasive Hib disease. Menhibrix also produced antibodies against the meningococcal component at levels, indicating that it would offer protection against meningococcal disease caused by serogroups C and Y of N meningitidis.
The vaccine’s safety was established by a study of roughly 7500 infants and toddlers in the United States, Mexico, and Australia. Pain, redness, and swelling at the injection site; irritability; and fever were common adverse reactions.
Menhibrix is administered in 4 doses at months 2, 4 and 6, with the fourth dose administered between months 12 and 16. The first dose can be given as early as 6 weeks, and the last as late as 18 months.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more